```html

Zollinger‑Ellison Syndrome (Type I Gastric Neuroendocrine Tumor)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑secreting tumors (gastrinomas) cause excessive gastric acid production. When the gastrin‑producing tumor arises in the stomach and is associated with chronic atrophic gastritis, the resulting lesions are classified as type I gastric neuroendocrine tumors (NETs). These tumors are usually small, well‑differentiated, and have a low potential for metastasis, but they can cause significant gastrointestinal symptoms because of the hyperacidic environment.

• Who it affects: Adults, with a median age of diagnosis around 55 years. Slight female predominance has been reported for type I gastric NETs.
• Prevalence: Gastric NETs represent < 1 % of all gastric malignancies. Type I accounts for 70‑80 % of gastric NETs, translating to roughly 0.5–1 case per 100,000 persons per year worldwide (Mayo Clinic; WHO 2022).
• Related conditions: Chronic autoimmune gastritis, pernicious anemia, and Helicobacter pylori infection are frequent precursors.

Symptoms

Because excess gastric acid damages the mucosa, symptoms can be diverse. Not every patient will have all of them.

• Epigastric (upper abdominal) pain: Burning or gnawing pain that may improve with antacids.
• Heartburn / gastro‑esophageal reflux disease (GERD): Frequent acid reflux, especially after meals.
• Peptic ulcer disease: Ulcers in the duodenum or stomach that can cause bleeding.
• Upper gastrointestinal (GI) bleeding: Hematemesis (vomiting blood) or melena (black tarry stools).
• Nausea & vomiting: Often related to ulcer pain or severe acid load.
• Weight loss: Due to chronic pain, malabsorption, or reduced food intake.
• Diarrhea: Occasionally from rapid gastric emptying.
• Iron‑deficiency anemia: Chronic blood loss from microscopic ulcerations.
• Pernicious anemia symptoms: Fatigue, glossitis, and neurological signs when autoimmune gastritis coexists.

Causes and Risk Factors

Type I gastric NETs develop in the setting of longstanding hypergastrinemia. The main pathways are:

Primary cause

• Chronic atrophic gastritis: Autoimmune destruction of parietal cells leads to low stomach acidity, which triggers compensatory gastrin release.
• Helicobacter pylori infection: Chronic infection can produce a similar atrophic pattern, especially in older adults.

Risk factors

• Female sex (slightly higher incidence).
• Age >50 years.
• History of autoimmune disorders (thyroiditis, type 1 diabetes, vitiligo).
• Long‑standing H. pylori infection or prior eradication therapy (the inflammation can persist).
• Genetic predisposition for multiple endocrine neoplasia type 1 (MEN 1) – although MEN 1 more commonly causes type II gastric NETs, it can occasionally mimic type I.

Diagnosis

Diagnosis requires a combination of clinical suspicion, laboratory testing, imaging, and histopathology.

Laboratory tests

• Serum gastrin level: Often >2× the upper limit of normal (>200 pg/mL) after a fasting sample. In type I NETs, levels are usually modestly elevated (<1,000 pg/mL).
• Secretin stimulation test: Helps differentiate ZES from other causes of hypergastrinemia (Mayo Clinic).
• Anti‑parietal cell and anti‑intrinsic factor antibodies: Positive in autoimmune gastritis.
• Complete blood count (CBC) & iron studies: Detect anemia from chronic bleeding.

Endoscopic evaluation

• Upper endoscopy (EGD): Visualizes multiple small (<1 cm) polypoid lesions in the gastric body and fundus; biopsies are taken.
• Chromogranin A (CgA) level: A neuroendocrine marker; may be mildly elevated but is not specific.

Imaging

• Endoscopic ultrasound (EUS): Determines depth of tumor invasion and guides fine‑needle aspiration.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Detects somatostatin‑receptor‑positive lesions and rules out metastasis.
• CT or MRI abdomen: For staging if larger lesions (>2 cm) or suspicious lymph nodes are present.

Pathology

Biopsy specimens show well‑differentiated neuroendocrine cells positive for chromogranin A and synaptophysin, with a low Ki‑67 proliferation index (<3 %). This confirms a grade 1 NET consistent with type I disease.

Treatment Options

Management balances controlling acid hypersecretion, removing or ablating the tumors, and monitoring for recurrence.

Medication

• Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (e.g., 40–80 mg daily) are first‑line to suppress acid, promote ulcer healing, and may reduce gastrin levels.
• H2‑receptor antagonists: Cimetidine or ranitidine (if PPIs are not tolerated).
• Somatostatin analogues (e.g., octreotide, lanreotide): Used when lesions are multiple or refractory; they inhibit gastrin release and can shrink tumors.

Endoscopic and Surgical Procedures

• Endoscopic polypectomy: Preferred for isolated lesions ≤1 cm.
• Endoscopic mucosal resection (EMR) or submucosal dissection (ESD): For slightly larger lesions (1–2 cm) while preserving stomach tissue.
• Partial or total gastrectomy: Reserved for >2 cm tumors, deep invasion, or when there is evidence of regional lymph node spread.
• Lymph node sampling: Performed intra‑operatively if imaging suggests nodal involvement.

Lifestyle & Supportive Measures

• Avoid NSAIDs, aspirin, and alcohol – they aggravate ulcer formation.
• Adopt a low‑fat, low‑spice diet while the ulcer heals; small, frequent meals reduce acid spikes.
• Maintain adequate iron and vitamin B12 intake; consider supplementation if pernicious anemia is present.
• Quit smoking – it impairs mucosal healing.

Living with Zollinger‑Ellison Syndrome (Type I Gastric Neuroendocrine Tumor)

Long‑term success relies on consistent medical follow‑up and self‑care habits.

Surveillance

• Endoscopy every 12 months for the first 2 years, then every 2‑3 years if stable (American Gastroenterological Association).
• Serum gastrin and chromogranin A levels checked every 6‑12 months.
• Annual CBC and iron studies to catch occult bleeding early.

Daily Management Tips

• Take PPIs exactly as prescribed – timing (30 min before breakfast) maximizes effect.
• Keep a symptom diary (pain, heartburn, stool color) to discuss with your gastroenterologist.
• Stay hydrated; chronic acid loss can lead to electrolyte imbalances.
• Exercise regularly (150 min moderate activity per week) to support overall gastrointestinal motility and bone health.
• Join support groups (e.g., NET Cancer Support Group) for emotional encouragement and up‑to‑date information.

Prevention

Since type I NETs are often a consequence of chronic gastritis, prevention focuses on reducing gastritis risk:

• Eradicate H. pylori infection when diagnosed (triple therapy: clarithromycin, amoxicillin, and a PPI for 14 days).
• Screen for and treat autoimmune gastritis early – monitor antibodies and vitamin B12 levels.
• Limit alcohol intake and avoid smoking.
• Use NSAIDs and aspirin only under medical supervision; consider gastroprotective agents if required.

Complications

If left untreated or poorly controlled, several serious problems may develop:

• Refractory peptic ulcer disease leading to perforation.
• Upper GI bleeding requiring transfusion or endoscopic hemostasis.
• Malabsorption of iron, calcium, and vitamin B12 → anemia, osteoporosis, neurologic deficits.
• Progression to higher‑grade neuroendocrine carcinoma (rare but reported in >2 cm lesions).
• Metastatic disease to lymph nodes, liver, or pancreas—more common in type II/III NETs but a consideration for large type I tumors.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH) – NIDDK, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Classification of Tumors of the Digestive System 2022, Cleveland Clinic, European Neuroendocrine Tumor Society (ENETS) Guidelines 2023.

```